626 related articles for article (PubMed ID: 37539955)
1. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
[TBL] [Abstract][Full Text] [Related]
2. Interventions for chronic kidney disease in people with sickle cell disease.
Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
[TBL] [Abstract][Full Text] [Related]
3. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
4. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
[TBL] [Abstract][Full Text] [Related]
7. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ; Kohli R; Hopewell S; Trivella M; Wang WC
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003146. PubMed ID: 32716555
[TBL] [Abstract][Full Text] [Related]
8. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
9. Preoperative blood transfusions for sickle cell disease.
Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
11. Preoperative blood transfusions for sickle cell disease.
Estcourt LJ; Fortin PM; Trivella M; Hopewell S
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003149. PubMed ID: 27049331
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Sasongko TH; Nagalla S
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD009191. PubMed ID: 34932828
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Sasongko TH; Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009191. PubMed ID: 26041152
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant supplementation for sickle cell disease.
Bolarinwa AB; Oduwole O; Okebe J; Ogbenna AA; Otokiti OE; Olatinwo AT
Cochrane Database Syst Rev; 2024 May; 5(5):CD013590. PubMed ID: 38775255
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Sasongko TH; Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2013 Mar; (3):CD009191. PubMed ID: 23543572
[TBL] [Abstract][Full Text] [Related]
19. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Geneen LJ; Dorée C; Estcourt LJ
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012349. PubMed ID: 36877640
[TBL] [Abstract][Full Text] [Related]
20. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Bourke JP; Bueser T; Quinlivan R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
